Patel Kashyap, Batty Kevin T, Moore Brioni R, Gibbons Peter L, Kirkpatrick Carl M
Centre for Medicine Use and Safety, Monash University, Melbourne, VIC, Australia
School of Pharmacy, Faculty of Health Sciences, Curtin University, Bentley, WA, Australia West Coast Institute, Joondalup, WA, Australia.
J Antimicrob Chemother. 2014 Aug;69(8):2155-63. doi: 10.1093/jac/dku120. Epub 2014 Apr 28.
To develop a mechanism-based model that describes the time course of the malaria parasite in infected mice receiving a combination therapy regimen of dihydroartemisinin and piperaquine.
Total parasite density-time data from Swiss mice inoculated with Plasmodium berghei were used for the development of population models in S-ADAPT. The mice were administered a single intraperitoneal dose of 30 mg/kg dihydroartemisinin, 10 mg/kg piperaquine phosphate or a combination of both antimalarials at 64 h post-inoculation. In a separate study, mice received multiple dihydroartemisinin doses (5 × 10 mg/kg or 30 mg/kg dihydroartemisinin followed by two 10 mg/kg doses). Parasite recrudescence after treatment was defined using a model that incorporated each erythrocytic stage of the P. berghei life cycle.
The disposition of dihydroartemisinin and piperaquine was described by a one-compartment and two-compartment model, respectively. The estimated clearance was 1.95 L/h for dihydroartemisinin and 0.109 L/h for piperaquine. A turnover model described the parasite killing curve after single-agent dosing, with an estimated mean IC50 of 0.747 μg/L for dihydroartemisinin and 16.8 μg/L for piperaquine. In addition, the rate of parasite killing by dihydroartemisinin was almost 50-fold faster than for piperaquine. Parameters from the monotherapy models adequately described the parasite density-time curve following dihydroartemisinin/piperaquine combination therapy or multiple-dose regimens of dihydroartemisinin.
This study has developed mechanistic models that describe the parasite-time curve after single, multiple or combination dosing of antimalarials to mice. These structural models have potential application for pre-clinical investigations to design and refine artemisinin-based combination therapy dosage regimens.
建立一个基于机制的模型,以描述感染疟疾的小鼠在接受双氢青蒿素和哌喹联合治疗方案后的疟原虫时间进程。
将接种伯氏疟原虫的瑞士小鼠的总寄生虫密度-时间数据用于在S-ADAPT中建立群体模型。在接种后64小时,给小鼠腹腔注射单剂量30mg/kg双氢青蒿素、10mg/kg磷酸哌喹或两种抗疟药的组合。在另一项研究中,小鼠接受多次双氢青蒿素剂量(5×10mg/kg或30mg/kg双氢青蒿素,随后两次10mg/kg剂量)。使用纳入伯氏疟原虫生命周期每个红细胞阶段的模型定义治疗后的寄生虫复发。
双氢青蒿素和哌喹的处置分别由单室模型和双室模型描述。双氢青蒿素的估计清除率为1.95L/h,哌喹为0.109L/h。一个周转模型描述了单药给药后的寄生虫杀伤曲线,双氢青蒿素的估计平均IC50为0.747μg/L,哌喹为16.8μg/L。此外,双氢青蒿素杀死寄生虫的速度比哌喹快近50倍。单药治疗模型的参数充分描述了双氢青蒿素/哌喹联合治疗或双氢青蒿素多剂量方案后的寄生虫密度-时间曲线。
本研究建立了机制模型,描述了对小鼠单剂量、多剂量或联合给药抗疟药后的寄生虫-时间曲线。这些结构模型在临床前研究中具有潜在应用,可用于设计和优化基于青蒿素的联合治疗剂量方案。